New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

Core Insights - The study presented by ALK indicates that 88% of participants prefer EURneffy, a needle-free adrenaline product, over traditional auto-injectors for anaphylaxis treatment [1][3]. User Preference and Study Findings - A randomized crossover study involving 90 participants showed a significant preference for EURneffy, with 88% favoring it over auto-injectors, regardless of prior experience with severe allergies or auto-injectors [3][4]. - Key factors influencing preference included ease of carrying and using EURneffy, the absence of a needle, and a less stigmatizing appearance [3][4]. - Participants rated EURneffy more favorably across ten statements addressing barriers to carrying adrenaline, with 98-100% noting advantages in size, weight, and temperature flexibility [4]. Clinical Implications - The findings suggest that EURneffy could help individuals with life-threatening allergies feel more confident and prepared in emergencies, addressing practical and psychological barriers to auto-injector use [2][4]. - Clinicians and payers are encouraged to consider expanding treatment options to improve the quality of life for those at risk of anaphylaxis [4][5]. Product Information - EURneffy is a nasal spray that is well absorbed and quickly distributed in the body, offering a portable alternative to injectable adrenaline [6]. - It has a total shelf life of 30 months, does not require special storage, and is unaffected by freezing [6]. Regulatory Approvals - EURneffy has received approvals in multiple regions, including the US, Japan, China, and the EU, for treating anaphylaxis in various age groups and weight categories [7][8].